These top stocks are looking increasingly attractive for a long-term investment.Not all stocks have responded to the bull market in the some way. While many businesses have followed the broader trend of steadily rising, some stocks are trading down considerably and even coming close to historical lows.When you're looking at stocks to buy, whether shares are discounted or soaring, it's important to understand why those trends are happening and what it means for your portfolio. On that note, if you're hunting ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against DexCom, Inc. (“DexCom” or the “Company”) (NASDAQ: DXCM) on behalf of DexCom stockholders. Our investigation concerns whether DexCom has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On July 25, 2024, after the closure of market trading, DexCom issued a press ...

文章核心观点 - 戴康公司第二季度营收表现不佳,导致股价大跌超过40% [1][2] - 公司预计第三季度营收将下降,全年营收指引也大幅下调 [3][4] - 公司面临多方面挑战,包括销售团队重组、新客户增长不及预期、G7产品返利等 [5][11] - 公司在耐用医疗设备(DME)渠道的表现也不理想 [5][6] 根据相关目录分别进行总结 公司业务和财务表现 - 公司第二季度营收同比增长15%,达到10亿美元,但低于分析师预期的10.4亿美元 [3] - 公司预计第三季度营收将下降至9.75亿-10亿美元,全年营收指引也从之前的42-43.5亿美元下调至40-40.5亿美元 [4] - 公司CEO表示销售团队重组、新客户增长不及预期、G7产品返利等因素导致业绩下滑 [5][11] - 公司在耐用医疗设备(DME)渠道的表现也不理想,失去了一些高收入客户 [6][11] 投资者反应和分析师评论 - 股价大跌超过40%,创历史新低,市值蒸发约180亿美元 [1][2] - 摩根大通下调评级,认为这是"错误方向的急转弯" [7] - 分析师认为公司面临的问题主要是内部因素造成的,而非外部市场变化 [7][8][14][15] - 分析师认为公司长期发展前景不变,短期问题应该是暂时的 [14][15]

文章核心观点 - DexCom公司在2024年第二季度的调整后每股收益超出市场预期 [1] - 公司收入同比增长15%,但未达到市场预期 [2] - 传感器和其他收入增长22%,硬件收入下降39% [4] - 美国收入增长19%,国际收入增长7% [5] - 公司调低了2024年全年收入指引 [10] 公司业务概况 - 公司主要从事实时连续血糖监测系统的研发和销售 [2][5][11][12] - 新产品G7在国际市场的推出带动了收入增长 [11][12] - 公司正在开发新的CGM产品Stelo,预计将在2024年贡献约1%的收入 [13] 财务表现 - 毛利润增长14.7%,毛利率保持稳定在63.5% [6] - 研发费用和销售管理费用分别增长13.9%和11.2% [7][8] - 调整后营业利润率为19.5%,同比提升70个基点 [8] - 公司现金及等价物余额为31.2亿美元 [9]

文章核心观点 - 公司第二季度收入增长15%至10亿美元,但低于分析师预期的10.4亿美元 [3] - 公司第二季度GAAP利润为1.435亿美元,非GAAP利润为1.743亿美元,同比增长 [4] - 公司下调了2024年全年收入预期,从原先的42亿-43.5亿美元下调至40亿-40.5亿美元 [5] - 公司在耐用医疗设备(DME)渠道失去了部分市场份额,新患者数量也低于预期 [6] 根据相关目录分别进行总结 公司财务表现 - 第二季度收入增长15%至10亿美元,但低于分析师预期的10.4亿美元 [3] - 第二季度GAAP利润为1.435亿美元,非GAAP利润为1.743亿美元,同比增长 [4] - 公司下调了2024年全年收入预期,从原先的42亿-43.5亿美元下调至40亿-40.5亿美元 [5] 公司经营情况 - 公司在耐用医疗设备(DME)渠道失去了部分市场份额 [6] - 新患者数量也低于预期,可能受到GLP-1药物的影响 [6]

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces an investigation into DexCom, Inc. (NASDAQ: DXCM) for potential violations of the federal securities laws. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Why Did DexCom’s Stock Drop? DexCom develops glucose monitoring systems for diabetes management. The company discussed how its recent sales force re ...

SAN DIEGO, July 26, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating whether DexCom, Inc. (NASDAQ: DXCM) or any of its executive officers or others violated securities laws by misrepresenting or failing to timely disclose material, adverse information to investors. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws. What if I purchased DexCom securities? If you purchased securities and suffered losses on you ...

DexCom (NASDAQ:DXCM) stock is falling on Friday after the company released its earnings report for Q2 2024.DexCom starts its earnings report with adjusted earnings per share of 43 cents. That’s better than Wall Street’s estimate of 39 cents per share. It’s also an improvement over its adjusted EPS of 34 cents in the same period of the year prior.However, the company’s revenue of $1 billion failed to impress. It doesn’t stack up to analysts’ estimate of $1.04 billion. Even if its a 15% increase year-over-yea ...

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Friday.Shares of DexCom, Inc. DXCM fell sharply during Friday's pre-market trading after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.DexCom reported quarterly earnings of 43 cents per share, which beat the analyst consensus estimate of 39 cents. Quarterly sales came in at $1.004 billion which missed the analyst consensus estimate of $1.036 billion.D ...

文章核心观点 - 公司在Q2财报中报告了令人失望的业绩,销售增长大幅放缓[2][3][4] - 公司下调了2024财年的全年业绩预期,主要受到分销渠道和药房返利等因素的影响[3][5] - 公司的新产品Stelo CGM设备的销售预期也被大幅下调[3] - 公司的盈利能力仍然保持较强,但估值水平面临下调压力[7][8][9][10] 根据目录分别总结 公司业绩概况 - 公司Q2总收入同比增长15%至10亿美元,为近10年最慢的季度增速[3] - 美国市场收入同比增长19%至7.32亿美元,国际市场收入同比增长7%至2.72亿美元[4] - 公司面临分销渠道效率下降和药房返利增加等挑战[5] 公司财务表现 - 公司Q2经营利润率和EBIT利润率均有所提升[7] - 公司净利润同比增长24%至1.435亿美元,每股收益0.43美元超预期[8] - 公司资产负债表健康,现金和短期证券合计约31亿美元,长期债务约24亿美元[8] 公司未来展望 - 公司下调2024财年全年收入增长预期至约11%[5] - 公司新产品Stelo CGM的销售预期也被大幅下调[3] - 未来几年公司收入和利润增速预计将有所放缓[9][10]